4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Dyne Therapeutics, Inc. (DYN) operates in the Biotechnology industry and is headquartered in Waltham, United States with about 263 employees. Its market capitalization is roughly $4 billion. In the fiscal year ended 2025-12-31, DYN reported $0M in revenue and ($446M) in net income.
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($468M) | ($344M) | ($242M) | ($171M) | — |
| Net Income | ($446M) | ($317M) | ($236M) | ($168M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($125M) | ($116M) | ($114M) | ($116M) | ($122M) |
| Net Income | ($121M) | ($112M) | ($108M) | ($111M) | ($115M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $1.2B | $691M | $165M | $306M | — |
| Total Liabilities | $215M | $61M | $74M | $54M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive DYN viewer.
About TickerBase · Data methodology & sources